RNA-Associated Y4: A Potential Drug Target for Various Diseases

Target Name: RNY4

NCBI ID: G6086

RNY4

Other Name(s): RNA, Ro60-associated Y4 | Y4 | HY4

RNA-Associated Y4: A Potential Drug Target for Various Diseases

RNA-associated Y4 (RNY4) is a protein that is expressed in various tissues throughout the body. It is a key regulator of RNA metabolism and has been implicated in a number of cellular processes, including cell growth, apoptosis, and inflammation. While much is still known about RNY4, its role in these processes has been identified, and it is a potential drug target.

RNY4 is a member of the Y family of proteins, which includes a number of structurally similar proteins that are involved in various cellular processes. These proteins all share a conserved catalytic core and a unique mechanism of interaction with small molecules, known as the nucleotide- binding oligomerization (NBO) domain. RNY4 is unique in that it is associated with RNA metabolism and has been shown to play a role in regulating the levels of RNA in various cells.

One of the key functions of RNY4 is its role in regulating the levels of RNA in the cytoplasm. The cytoplasm is the space between the cell nucleus and the cell membrane, and it is where many cellular processes are carried out. RNY4 is involved in regulating the movement of RNA into the cytoplasm, as well as the delivery of RNA from the cytoplasm to the cell nucleus. This is important for the proper functioning of many cellular processes, including cell growth, apoptosis, and inflammation.

In addition to its role in regulating RNA levels, RNY4 is also involved in the regulation of cellular processes that are independent of RNA metabolism. For example, RNY4 has been shown to be involved in the regulation of cellular adhesion, which is the ability of cells to stick to other cells and form tissues. RNY4 has also been shown to be involved in the regulation of cell adhesion, which is the ability of cells to stick together and form tissues.

The association of RNY4 with RNA metabolism has led to its potential as a drug target. Many diseases are caused by the disruption of normal cellular processes, and RNA metabolism is a critical component of these processes. By targeting RNY4, researchers may be able to develop new treatments for a variety of diseases.

While much is still known about RNY4, its potential as a drug target is already being investigated. Studies have shown that inhibiting the activity of RNY4 has the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition , RNY4 has also been shown to be involved in the regulation of cellular processes that are independent of RNA metabolism, which may have implications for the development of new treatments for diseases that are caused by the disruption of normal cellular processes.

In conclusion, RNA-associated Y4 (RNY4) is a protein that is involved in various cellular processes and has been implicated in the regulation of RNA metabolism. Its potential as a drug target is being investigated in order to treat a variety of diseases. While more research is needed, its association with RNA metabolism makes it a promising target for future research.

Protein Name: RNA, Ro60-associated Y4

The "RNY4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNY4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets